Horizon Pharma announced that the FDA has approved Rayos (prednisone) delayed-release tablets for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).
The FDA approval was supported by data bridging the pharmacokinetics of Rayos to immediate-release prednisone and data from the Circadian Administration of Prednisone in RA (CAPRA-1 and 2) trials. The CAPRA-2 trial demonstrated that people with moderate to severe RA treated with Rayos experienced a statistically significant improvement in ACR20 response criteria compared to placebo. The CAPRA-1 trial supported the overall safety of Rayos.
Rayos is a proprietary formulation of the glucocorticoid prednisone, available in 1mg, 2mg, and 5mg strengths.
For more information call (866) 479-6742 or visit www.horizonpharma.com.